ClinicalTrials.gg
CompletedNCT03371472VALEUpdated Jan 17, 2019

Evaluation of the Usefulness of Imaging Methods and 3D Reconstruction in Percutaneous Closure Procedures of PVL.

An interventional study of Visualisation and measuring of paravalvular leak. in PVL - Paravalvular Leak, sponsored by Balton Sp.zo.o.. Completed at 2 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-17.

Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2017, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Paravalvular leak (PVL) is a condition that could be treated surgically or by the transcatheter deployment of the occluder devices (plugs).

No PVL-specific occluder device is available on the market. VALE consortium plans to design and validate a new PVL dedicated devices (sizing balloon and occluder) in the context of computer 3D modeling, bench testing, preclinical evaluation and clinical research.

Read the detailed description

Transcatheter closure of PVL has emerged as a new treatment strategy that can be offered to patients with isolated PVL or to those with a very high risk of repeat surgery. The transcatheter approach involves deployment of occlude devices or coils and adopting either a percutaneous or a transapical approach. Limitation of such approach is the fact that no PVL-dedicated device is available on the market, and either vascular-specific plugs or other types of occluders used commonly for closure of ventricular septal defects or patent ductus arteriosus can be used. Several technical issues can make the procedure challenging.

The primary problem is the localization and track of the canal which can be very difficult to engage and cross with the guidewire. Also the maneuverability of the guide catheter in often enlarged left atrium and the passage of the occluder device through narrow and serpiginous canal between calcified annulus and sewing ring is challenging.

Clearly the limitations of current devices and increasing number of patients with significant PVL warrant the attempts to design and validate new PVL-dedicated devices in the context of computer modeling, bench testing, preclinical evaluation and clinical translation. These devices, as sizing balloon, could significantly simplify and shorten the procedure, decrease the risk of complications and incomplete defect closure as well as optimize cost-effectiveness of the procedure by decreasing number of the occluders.

02

Conditions studied

  • PVL - Paravalvular Leak
03

In context

Lead sponsor

Balton Sp.zo.o. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The presence of clinically and haemodynamically significant leakage around the surgically implanted cardiac prosthesis in the mitral or aortic position.
  • Heart surgery (heart team) disability after another cardiac surgery.
  • Technical feasibility of paravalvular leakage closure according to experienced operator.

Exclusion criteria

Exclusion Criteria:

  • Active endocarditis on artificial valve
  • Instability of artificial valve
  • The amount of cavity that prevents effective closure with an occluder
  • A history of acute coronary syndrome in less than 3 months before enrollment
  • Confirmed echocardiography of transplatin or transesophageal echocardiography
  • to contrast media
  • Any condition associated with the expected of less than 6 months
  • Haemorrhagic diathesis
  • Significant renal impairment ( \<30 mL/min/1.73m2)/chronic kidney disease at >G3 stage
  • Pregnancy or lactation
  • Under 18 years of age
  • Patient unable or unwilling to give an to participate in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Other
    VALE - PVL leak sizing balloon - mitral

    Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in mitral position - Balton developed investigational balloon

    Device: Visualisation and measuring of paravalvular leak.

  • Other
    VALE - PVL leak sizing balloon - aortic

    'Placement and inflation of PVL leak sizing balloon for visualisation and measuring of paravalvular leak located in aortic position - Balton developed investigational balloon

    Device: Visualisation and measuring of paravalvular leak.

Interventions

  • DeviceVisualisation and measuring of paravalvular leak.

    Visualisation and measurements of PVL by investigational sizing ballons made by Balton. The balloon is a modification of diameter and length of existing sizing ballons (AcuMark™, AMPLATZER™, Occlutech®).

06

What researchers measure

Primary outcomes

  1. Number of subjects with sizing procedure success (efficacy outcome)

    Sizing procedure is defined as effective when all following steps: device introduction into the leakage channel, filling in the leakage channel, obtaining a balloon image in the X-ray recording and removal of the balloon without complications are performed.

    Time frame: During index procedure

  2. Incidence of a combined investigational device safety endpoint (safety outcome)

    Safety of the investigational device defined as the occurrence/frequency of locking, fragmentation of the dimensioning balloon, enlargement of the leakage channel, locking of the mechanical prosthesis disks. Failure to use the investigational device defined as: locking of the dimensional balloon in site, fragmentation of the dimensional balloon, enlargement of the leakage channel dimension directly related to the application of the dimensional balloon, locking of the mechanical prosthesis disks. The failure will be assessed per investigational device and accounted for if at least one of four described events occur. Moreover, the frequency of each event will be additionally assessed and presented in per investigational device analysis.

    Time frame: During index procedure

Secondary outcomes

  1. Frequency of major undesirable cardiovascular events

    MACCE defined as: cardiac and non-cardiac death, stroke, TIA, myocardial infarction

    Time frame: 30 days observation

  2. Frequency and severity of hemorrhagic complications

    The hemorrhagic complications rated using BARC scale during 30 days follow up

    Time frame: 30 days observation

  3. Size of paravalvular leakage after procedure

    Evaluated in transesophageal echocardiography

    Time frame: During index procedure

  4. Comparison of the size of the paravalvular leakage channel illustrated by a dimensional balloon obtained using 3D-TEE and computerized tomography echocardiography

    Comparison of the measurements by sizing balloon to TEE and CT.

    Time frame: During index procedure

  5. Total radiation dose.

    The amount of total radiation dose during index procedure.

    Time frame: During index procedure

  6. Total radiation time.

    The total radiation time of the index procedure.

    Time frame: During index procedure

  7. Duration of the dimensional procedure.

    The duration of the dimensional procedure during index procedure.

    Time frame: During index procedure

07

Study locations

2 sites
  • II Oddział Kliniczny Kardiologii i Interwencji Sercowo-Naczyniowych, Szpital Uniwersytecki w Krakowie
    Kraków, Małopolskie 31-501, Poland
  • III Oddział Kardiologii, Samodzielny Publiczny Szpital Kliniczny nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca
    Katowice, Śląskie 40-635, Poland
08

References and documents

Publications

  • Smolka G., Wojakowski W., Ochała A., Roleder T., Gąsior Z. Diagnosis and percutaneous treatment of paravalvular leaks; Post Kardiol Interw 2011; 7, 1 (23): 56-60
  • Scognamiglio G, Santoro G, Fusco F, Russo MG, Sarubbi B. Percutaneous treatment of multi-valvular paraprosthetic leaks in a "fragile" heart. Int J Cardiol. 2016 Nov 1;222:790-791. doi: 10.1016/j.ijcard.2016.07.283. Epub 2016 Aug 2. No abstract available. PubMed 27521562 ↗
  • Murakami T, Fujii H, Sakaguchi M, Takahashi Y, Suehiro Y, Nishimura S, Sakon Y, Yasumizu D, Sohgawa E, Shibata T. Intravascular ultrasound for transcatheter paravalvular leak closure. Gen Thorac Cardiovasc Surg. 2017 Aug;65(8):466-469. doi: 10.1007/s11748-016-0700-x. Epub 2016 Aug 8. PubMed 27501692 ↗
  • Giacchi G, Freixa X, Hernandez-Enriquez M, Sanchis L, Azqueta M, Brugaletta S, Martin-Yuste V, Masotti M, Sabate M. Minimally Invasive Transradial Percutaneous Closure of Aortic Paravalvular Leaks: Following the Steps of Percutaneous Coronary Intervention. Can J Cardiol. 2016 Dec;32(12):1575.e17-1575.e19. doi: 10.1016/j.cjca.2016.03.013. Epub 2016 Apr 1. PubMed 27378589 ↗
  • Smolka G, Pysz P, Kozlowski M, Jasinski M, Gocol R, Roleder T, Kargul A, Ochala A, Wojakowski W. Transcatheter closure of paravalvular leaks using a paravalvular leak device - a prospective Polish registry. Postepy Kardiol Interwencyjnej. 2016;12(2):128-34. doi: 10.5114/aic.2016.59363. Epub 2016 May 11. PubMed 27279872 ↗
  • Cruz-Gonzalez I, Rama-Merchan JC, Calvert PA, Rodriguez-Collado J, Barreiro-Perez M, Martin-Moreiras J, Diego-Nieto A, Hildick-Smith D, Sanchez PL. Percutaneous Closure of Paravalvular Leaks: A Systematic Review. J Interv Cardiol. 2016 Aug;29(4):382-92. doi: 10.1111/joic.12295. Epub 2016 May 31. PubMed 27242018 ↗
  • Taramasso M, Maisano F, Pozzoli A, Alfieri O, Meier B, Nietlispach F. Catheter-based treatment of paravalvular leaks. EuroIntervention. 2016 May 17;12 Suppl X:X55-X60. doi: 10.4244/EIJV12SXA11. PubMed 27174113 ↗
  • Hilling-Smith R, Chong A, Cox S. Mitral paravalvular leak closure by antegrade percutaneous approach using amplatzer PFO closure device. Catheter Cardiovasc Interv. 2017 Aug 1;90(2):E62-E67. doi: 10.1002/ccd.26417. Epub 2016 Apr 16. PubMed 27084789 ↗
  • Abdelghani M, Soliman OI, Schultz C, Vahanian A, Serruys PW. Adjudicating paravalvular leaks of transcatheter aortic valves: a critical appraisal. Eur Heart J. 2016 Sep 7;37(34):2627-44. doi: 10.1093/eurheartj/ehw115. Epub 2016 Apr 13. PubMed 27075871 ↗

Individual participant data

Plan to share: Undecided — IPD sharing data policy is currently restricted under grant consortium agreement and pending GDPR implementation in Europe.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Jun 2018, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2017
First posted
Dec 13, 2017
StartActual
May 8, 2017
Primary completionActual
Jun 12, 2018
CompletionActual
Jul 14, 2018
Last update
Jan 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03371472
Lead sponsor
Balton Sp.zo.o.
Collaborators
KCRI
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
May 8, 2017
Primary completion
Jun 12, 2018
Completion
Jul 14, 2018
Last update
Jan 17, 2019

Study contacts

Wojciech Wojakowski, Prof.
principal investigator · III Oddział Kardiologii, Samodzielny Publiczny Szpital Kliniczny nr 7 Śląskiego Uniwersytetu Medycznego w Katowicach, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion